Key Takeaways
- HHS plans to appoint deputy commissioners for technology and drugs at the FDA.
- Jared Seehafer is a leading candidate for the technology role.
- The FDA has faced scrutiny over its handling of foodborne outbreaks and drug approvals.
- New roles will report to FDA commissioner nominee Heidi Overton.
New Roles at the FDA
The Department of Health and Human Services (HHS) is preparing to establish two new deputy commissioner positions at the Food and Drug Administration (FDA). One role will focus on technology, particularly the intersection of health and artificial intelligence, while the other will concentrate on drug oversight.
Leadership Structure Changes
These new positions will report to Heidi Overton, who has been nominated as the FDA commissioner but still requires Senate confirmation. Although no official announcements have been made, sources indicate that this move is part of an effort by some in the Trump administration to increase influence over the agency.
Potential Candidates
Jared Seehafer, a senior advisor at the FDA and a veteran in the medical devices sector, is reportedly a strong candidate for the technology role. He co-founded Enzyme, a compliance software company, and previously worked at a venture capital firm before joining the FDA last year. The candidate for the deputy commissioner for drugs has not been disclosed.
Recent FDA Challenges
The FDA has been under scrutiny for its management of a cyclospora outbreak linked to iceberg lettuce, raising concerns about budget cuts affecting its ability to manage foodborne illnesses. Additionally, the agency has faced criticism for its decisions regarding new drug approvals, including a recent accelerated approval for a melanoma treatment after previous rejections.
AI Integration in FDA Operations
As part of its modernization efforts, the FDA has increasingly utilized artificial intelligence in its internal operations. The agency has implemented tools like Elsa for tasks such as document summarization. The new deputy commissioner for technology will oversee both the internal use of AI and the evaluation of AI-enabled medical products.
Regulatory Approaches for AI
Last week, the FDA released a discussion paper seeking stakeholder input on regulating generative AI-enabled medical devices, indicating a shift towards collaborative regulatory approaches rather than formal guidance.
